Very long response with trastuzumab for metastaticHer2-positive breast cancer

Metastatic Her2-positive breast cancer are very aggressive tumors. With the development of anti-Her2 therapies, the prognosis of such tumors has changed. The author reports the case of a 60-year-old woman, diagnosed with a left Her2-positive breast cancer, revealed by a pathological fracture of the right femur (pT1cN1aM1, Stage IV). She received hormonal treatment in association with trastuzumab. She always is under trastuzumab therapy for four years. Anti-Her2 therapies are effective even in metastatic cancer patients.

Her2-positive; Breast cancer; Metastasis; Trastuzumab; Long response; Targeted therapy.

[1] Dawood S, Broglio K, Buzdar AU, Hortobagyi G.N., Giordano S.H.: “Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review”. J. Clin. Oncol., 2010, 28, 92.

[2] Balduzzi S., Mantarro S., Guarneri V., Tagliabue L., Pistotti V., Moja L., D'Amico R.: “Trastuzumab-containing regimens for metastatic breast cancer”. Cochrane Database Syst. Rev., 2014, 6, CD006242.

[3] Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al.: “Pertuzumab plus docetaxel for metastatic breast cancer”. N. Engl. J. Med., 2012, 366, 109.

[4] Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., et al.: “Pertuzumab, trastuzumab, and docetaxel in Her2-positive metastatic breast cancer”. N. Engl. J. Med., 2015, 372, 724.

[5] Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al.: “Trastuzumab emtansine for Her2-positive advanced breast cancer”. N. Engl. J. Med., 2012, 367, 1783.